65,437 trials
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Trough Forced Expiratory Volume in One Second (FEV1) — 1.204; 1.063 Liters
Epilepsy · Partial Seizure Disorder · Epilepsies, Partial
Primary: Percent Change From Baseline in 28-day Seizure Frequency at Week 21. — -58.65; -57.43 percent change — p=0.8708
Sleep Disorders · PTSD · Suicide
Primary: Number of Nights With Nightmares — 2.61; .83; 0.97 nights/week
Hepatitis B, Chronic
Primary: Number of Participants With Serious Adverse Events (SAE) and Discontinuations Due to Adverse Events (AEs) - On Treatment — 2; 0; 0; 0 participants
Psoriasis
Primary: Clinical Success — 18; 3 participants — p=0.0003
Chronic Heart Failure
Primary: Natriuretic Brain Pro-peptid — 312; 200 pg/ml
HIV Infections
Primary: Percent of Participants With Regimen Failure, Defined as a Confirmed Virologic Failure or Discontinuation of Randomized NRTI Component of Study Treatment — 26.0; 29.8…
Stenosis of Vascular Prosthetic Devices, Implants and Grafts
Primary: ACPP Was Defined as the Interval Following the Index Procedure Until the Next Access Thrombosis or Reintervention. — 0.240; 0.110 proportion of participants
Multiple Myeloma
Primary: Percentage of Participants With Overall Disease Response at Month 6 — 20.0; 70.0; 10.0 Percentage of participants
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
Skin Diseases, Infectious · Skin Diseases, Bacterial
Primary: Clinical Response Rate at Test of Cure in the Clinically Evaluable Analysis Set — 98.2; 94.4; 94.4 Percentage of participants
Osteoarthritis
Primary: Change From Baseline in the Average Daily Worst Pain Intensity Score at Week 4 — 6.4; 6.5; -1.8; -1.8 Score on a scale
Pain · Obesity
Primary: Quality of Recovery 40 on the Day After Surgery — 165; 146 units on scale 40 (low) - 200 (high) — p=.01
Contrast Media
Primary: Number of Participants With Moderate to Severe Renal Impairment, Who Develop NSF (Nephrogenic Systemic Fibrosis), Based on Diagnostically Specific Clinical and…
Colorectal Cancer
Primary: Progression-Free Survival (PFS) From the Start of Treatment Beyond Progression — 6.3; 5.1 months